Sign In
Buy GUTS
$0.760
-0.0297 (-3.76%)
At Close: Jun 03, 2026
Participants retained ~78% of GLP-1 induced total body weight loss one year after discontinuation and a single Revita procedure
Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy
07:00am, Monday, 01'st Jun 2026
BURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approache
Fractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
04:40pm, Thursday, 14'th May 2026
Fractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript
09:50pm, Tuesday, 12'th May 2026
Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript
Fractyl Health Q1 Earnings Call Highlights
08:25pm, Tuesday, 12'th May 2026
Fractyl Health NASDAQ: GUTS said it remains on track to report pivotal data for its Revita therapy in early fourth quarter 2026, as management highlighted clinical, regulatory and reimbursement develo
Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates
04:05pm, Tuesday, 12'th May 2026
Next anticipated Revita ® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026 and 1-year randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026 Early Q4 2026 timing for t
Authorization advances Fractyl Health to a dual clinical-stage company, with Revita ® in pivotal development for post-GLP-1 weight maintenance and Rejuva ® entering first-in-human studies for type 2
BURLINGTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat o
Fractyl Health, Inc. (NASDAQ:GUTS) Receives $5.40 Average Price Target from Analysts
03:32am, Monday, 30'th Mar 2026
Shares of Fractyl Health, Inc. (NASDAQ: GUTS - Get Free Report) have earned an average rating of "Hold" from the five brokerages that are presently covering the company, Marketbeat reports. One analys
Scalable Biotech Manufacturing Unlocks a $14B Market
09:15am, Friday, 27'th Mar 2026
/PRNewswire/ -- USANewsGroup.com News Commentary - The global cell therapy manufacturing market is hitting a pivotal inflection point. It's projected to
Fractyl Health Q4 Earnings Call Highlights
03:07am, Thursday, 26'th Mar 2026
Fractyl Health (NASDAQ: GUTS) used its fourth-quarter and full-year 2025 results call to sharpen its investment narrative around Revita, its endoscopic procedure aimed at helping patients maintain wei
Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript
06:54pm, Tuesday, 24'th Mar 2026
Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript
Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026
07:00am, Tuesday, 17'th Mar 2026
BURLINGTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat
Fractyl Health, Inc. (GUTS) Moves to Buy: Rationale Behind the Upgrade
01:00pm, Monday, 16'th Mar 2026
Fractyl Health, Inc. (GUTS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance
07:00am, Thursday, 26'th Feb 2026
Topline 6-month pivotal data expected in early Q4 2026 with potential FDA marketing application submission expected in late Q4 2026 Company reiterates cash runway guidance into early 2027, beyond anti
